Matches in SemOpenAlex for { <https://semopenalex.org/work/W1652798144> ?p ?o ?g. }
- W1652798144 abstract "The majority of breast cancers express and rely on ERα for tumor growth, thus endocrine therapy is the mainstay of ER-positive breast cancer treatment. Despite the effectiveness of current therapies, many patients relapse with tumors still dependent on ER for growth via both estrogen-dependent and estrogen-independent mechanisms. Acquired mutations in ESR1 were recently identified in the ligand-binding domain of ERα in patients who progressed after aromatase inhibitors and tamoxifen. It is estimated that more than 20% of relapsed ER-positive breast cancer patients acquire activating mutations in ESR1. We created a variety of model systems to study the functional consequences of ESR1 mutations. In stable overexpressing cell lines, the mutant ER protein eventually becomes down-regulated, thus we generated cell lines with dox-inducible and CRISPR engineered ESR1 hotspot mutations. We confirmed ligand-independent transcriptional activity of ESR1 hotspot mutations including Y537S and D538G. Cell lines and patient derived xenograft (PDX) models were utilized in ER ChIP-seq studies. Additionally, we investigated therapeutic response and resistance in the context of ESR1 activating mutations for tamoxifen, fulvestrant, and next generation oral SERDs including ARN-810, also known as GDC-0810. ARN-810 is efficacious in MCF7 ESR1 Y537S xenografts and WHIM20 Y537S PDX tumors, indicating that SERDs may be effective for ER mutants. Citation Format: Wei Zhou, Robert A. Blake, Jim Nonomiya, Jing Qian, Lorna Kategaya, Ingrid Wertz, Anneleen Daemen, Thomas O9Brien, John Sensintaffar, Michael Moon, Michelle A. Nannini, Jason Oeh, Deepak Sampath, Xiaojing Wang, Nicholas Smith, Daniel Brigham, James Joseph, Jeffrey H. Hager, Lori S. Friedman. Selective estrogen receptor degrader (SERD) activity in ESR1 mutant models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1864. doi:10.1158/1538-7445.AM2015-1864" @default.
- W1652798144 created "2016-06-24" @default.
- W1652798144 creator A5001637232 @default.
- W1652798144 creator A5005907997 @default.
- W1652798144 creator A5006915014 @default.
- W1652798144 creator A5008557181 @default.
- W1652798144 creator A5018289200 @default.
- W1652798144 creator A5022839853 @default.
- W1652798144 creator A5035307605 @default.
- W1652798144 creator A5037379407 @default.
- W1652798144 creator A5037996246 @default.
- W1652798144 creator A5041063046 @default.
- W1652798144 creator A5055370060 @default.
- W1652798144 creator A5058060903 @default.
- W1652798144 creator A5061081453 @default.
- W1652798144 creator A5067239526 @default.
- W1652798144 creator A5073771007 @default.
- W1652798144 creator A5078473824 @default.
- W1652798144 creator A5079488873 @default.
- W1652798144 creator A5083134393 @default.
- W1652798144 creator A5087085239 @default.
- W1652798144 date "2015-08-01" @default.
- W1652798144 modified "2023-09-26" @default.
- W1652798144 title "Abstract 1864: Selective estrogen receptor degrader (SERD) activity in ESR1 mutant models" @default.
- W1652798144 doi "https://doi.org/10.1158/1538-7445.am2015-1864" @default.
- W1652798144 hasPublicationYear "2015" @default.
- W1652798144 type Work @default.
- W1652798144 sameAs 1652798144 @default.
- W1652798144 citedByCount "0" @default.
- W1652798144 crossrefType "proceedings-article" @default.
- W1652798144 hasAuthorship W1652798144A5001637232 @default.
- W1652798144 hasAuthorship W1652798144A5005907997 @default.
- W1652798144 hasAuthorship W1652798144A5006915014 @default.
- W1652798144 hasAuthorship W1652798144A5008557181 @default.
- W1652798144 hasAuthorship W1652798144A5018289200 @default.
- W1652798144 hasAuthorship W1652798144A5022839853 @default.
- W1652798144 hasAuthorship W1652798144A5035307605 @default.
- W1652798144 hasAuthorship W1652798144A5037379407 @default.
- W1652798144 hasAuthorship W1652798144A5037996246 @default.
- W1652798144 hasAuthorship W1652798144A5041063046 @default.
- W1652798144 hasAuthorship W1652798144A5055370060 @default.
- W1652798144 hasAuthorship W1652798144A5058060903 @default.
- W1652798144 hasAuthorship W1652798144A5061081453 @default.
- W1652798144 hasAuthorship W1652798144A5067239526 @default.
- W1652798144 hasAuthorship W1652798144A5073771007 @default.
- W1652798144 hasAuthorship W1652798144A5078473824 @default.
- W1652798144 hasAuthorship W1652798144A5079488873 @default.
- W1652798144 hasAuthorship W1652798144A5083134393 @default.
- W1652798144 hasAuthorship W1652798144A5087085239 @default.
- W1652798144 hasConcept C104317684 @default.
- W1652798144 hasConcept C121608353 @default.
- W1652798144 hasConcept C126322002 @default.
- W1652798144 hasConcept C143065580 @default.
- W1652798144 hasConcept C172313692 @default.
- W1652798144 hasConcept C2775930923 @default.
- W1652798144 hasConcept C2776166826 @default.
- W1652798144 hasConcept C2777164284 @default.
- W1652798144 hasConcept C2777176818 @default.
- W1652798144 hasConcept C2779744173 @default.
- W1652798144 hasConcept C2780482068 @default.
- W1652798144 hasConcept C502942594 @default.
- W1652798144 hasConcept C530470458 @default.
- W1652798144 hasConcept C54355233 @default.
- W1652798144 hasConcept C71924100 @default.
- W1652798144 hasConcept C84606932 @default.
- W1652798144 hasConcept C86803240 @default.
- W1652798144 hasConceptScore W1652798144C104317684 @default.
- W1652798144 hasConceptScore W1652798144C121608353 @default.
- W1652798144 hasConceptScore W1652798144C126322002 @default.
- W1652798144 hasConceptScore W1652798144C143065580 @default.
- W1652798144 hasConceptScore W1652798144C172313692 @default.
- W1652798144 hasConceptScore W1652798144C2775930923 @default.
- W1652798144 hasConceptScore W1652798144C2776166826 @default.
- W1652798144 hasConceptScore W1652798144C2777164284 @default.
- W1652798144 hasConceptScore W1652798144C2777176818 @default.
- W1652798144 hasConceptScore W1652798144C2779744173 @default.
- W1652798144 hasConceptScore W1652798144C2780482068 @default.
- W1652798144 hasConceptScore W1652798144C502942594 @default.
- W1652798144 hasConceptScore W1652798144C530470458 @default.
- W1652798144 hasConceptScore W1652798144C54355233 @default.
- W1652798144 hasConceptScore W1652798144C71924100 @default.
- W1652798144 hasConceptScore W1652798144C84606932 @default.
- W1652798144 hasConceptScore W1652798144C86803240 @default.
- W1652798144 hasLocation W16527981441 @default.
- W1652798144 hasOpenAccess W1652798144 @default.
- W1652798144 hasPrimaryLocation W16527981441 @default.
- W1652798144 hasRelatedWork W2012767871 @default.
- W1652798144 hasRelatedWork W2073884984 @default.
- W1652798144 hasRelatedWork W2106336024 @default.
- W1652798144 hasRelatedWork W2224069256 @default.
- W1652798144 hasRelatedWork W2396900282 @default.
- W1652798144 hasRelatedWork W2400399169 @default.
- W1652798144 hasRelatedWork W2494514989 @default.
- W1652798144 hasRelatedWork W2529323719 @default.
- W1652798144 hasRelatedWork W2563294220 @default.
- W1652798144 hasRelatedWork W2741042266 @default.
- W1652798144 hasRelatedWork W2741768782 @default.
- W1652798144 hasRelatedWork W2742126808 @default.
- W1652798144 hasRelatedWork W2886579073 @default.
- W1652798144 hasRelatedWork W2911573147 @default.